Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been assigned an average rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $32.20.

Several equities analysts have recently issued reports on the company. Wolfe Research assumed coverage on Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus set a $37.00 target price on Denali Therapeutics in a report on Monday, November 17th. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price target on shares of Denali Therapeutics in a research report on Thursday, January 8th. Finally, BTIG Research upped their price target on shares of Denali Therapeutics from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday, March 2nd.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares in the company, valued at $4,897,744.50. This represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several large investors have recently modified their holdings of DNLI. Vanguard Group Inc. grew its holdings in shares of Denali Therapeutics by 8.9% in the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after acquiring an additional 1,064,972 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Denali Therapeutics by 6.2% during the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Denali Therapeutics by 28.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after purchasing an additional 1,615,565 shares during the period. Temasek Holdings Private Ltd increased its stake in Denali Therapeutics by 30.9% in the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after purchasing an additional 1,657,142 shares in the last quarter. Finally, State Street Corp increased its stake in Denali Therapeutics by 14.6% in the 4th quarter. State Street Corp now owns 6,263,371 shares of the company’s stock worth $103,408,000 after purchasing an additional 799,110 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Trading Up 0.6%

Denali Therapeutics stock opened at $21.43 on Wednesday. The firm has a 50 day simple moving average of $19.59 and a 200-day simple moving average of $17.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The stock has a market capitalization of $3.40 billion, a PE ratio of -7.22 and a beta of 1.02. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same period in the prior year, the firm posted ($0.67) EPS. As a group, equities research analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.